Mutational heterogeneity in cancer and the search for new cancer-associated genes
2013 · Nature · 5,585 citations
https://doi.org/10.1038/nature12213
P
Peter S. Hammerman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
668
Papers
30.9K
Citations
71
h-index
110
i10-index
Peter S. Hammerman is an academic researcher from Casma Therapeutics (United States). The author has contributed to research in topics: RNA modifications and cancer & Lung Cancer Treatments and Mutations & Fibroblast Growth Factor Research. The author has an h-index of 71, co-authored 568 publications.
ORCID: 0009-0006-9143-899XPapers by this author
worksAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · Nature Communications · 1,522 citations
https://doi.org/10.1038/ncomms10501
Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival
2003 · Molecular and Cellular Biology · 566 citations
https://doi.org/10.1128/mcb.23.20.7315-7328.2003
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
2017 · Nature Communications · 325 citations
https://doi.org/10.1038/ncomms14121
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes
2017 · Molecular Cancer Research · 212 citations
https://doi.org/10.1158/1541-7786.mcr-17-0134
A genetic basis for the variation in the vulnerability of cancer to DNA damage
2016 · Nature Communications · 183 citations
https://doi.org/10.1038/ncomms11428
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat